Get the Stockscreener App
493.22
2.10%
10.15
Pre-market:
494.95
1.73
+0.35%
Regeneron Pharmaceuticals Inc stock is traded at $493.22, with a volume of 1.50M.
It is up +2.10% in the last 24 hours and down -11.69% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$483.07
Open:
$485.54
24h Volume:
1.50M
Relative Volume:
1.18
Market Cap:
$52.93B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
12.56
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
+0.60%
1M Performance:
-11.69%
6M Performance:
-36.60%
1Y Performance:
-50.72%
1-Day Range:
$485.00
$499.88
1-Week Range:
$476.49
$502.56
52-Week Range:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $800 From $950, Maintains Overweight Rating - marketscreener.com
Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity - marketscreener.com
Hennion & Walsh Asset Management Inc. Sells 763 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Intellectus Partners LLC Acquires 978 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 1-Year Low on Analyst Downgrade - MarketBeat
Promising Results in REGN's Dupixent Trial for Diverse Skin Tones | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Lmcg Investments LLC - MarketBeat
TB Alternative Assets Ltd. Invests $2 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Merit Financial Group LLC Has $1.03 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color | REGN Stock News - GuruFocus
Dupixent Clinical Trial Shows 76% Success Rate in Diverse Skin Types | REGN Stock News - Stock Titan
Lake Hills Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - AOL.com
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Procyon Advisors LLC - MarketBeat
Regeneron (REGN) Involved in DNA Data Auction Amid 23andMe Bankruptcy | REGN Stock News - GuruFocus
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week - MSN
Regeneron Pharmaceuticals Stock: Is REGN Underperforming the Healthcare Sector? - MSN
Czech National Bank Purchases 1,338 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Retinal Vein Occlusion Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Clinical Revenue, Statistics, Medication, Therapies, Prevalence, and Companies by DelveInsight - Barchart.com
Fate of 23andMe genetic data still not settled amid bankruptcy fight - The Washington Post
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's
The New Twist In Regeneron's 23andMe Bankruptcy Buyout - Investor's Business Daily
Regeneron (REGN) Sees Modest Daily Gain on Nasdaq, Bucking Recent Downward Trend - Daily Chhattisgarh News
23andMe to restart auction after former CEO wins challenge to Regeneron bid - FirstWord Pharma
23andMe Sets New Auction With $305 Million New Bid From Ex-CEO - Bloomberg
UBS Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $560.00 - MarketBeat
UBS Maintains Neutral Rating, Lowers Price Target for REGN | REGN Stock News - GuruFocus
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock? - Yahoo Finance
23andMe seeks second auction as ex-CEO outbids Regeneron - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Raised by Woodstock Corp - MarketBeat
Baker Tilly Wealth Management LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rhumbline Advisers Purchases 2,547 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andMe seeks new bids after $305 million offer from its co-founder - Reuters
23andMe'S Bankruptcy Sale Sparks Bidding War - Finimize
Investor Alert: Johnson Fistel Investigates Regeneron - GlobeNewswire
Federal Judge Allows Antitrust Case Against Claritev and Health Insurers to Move Forward - PYMNTS.com
Why Regeneron Is Falling And Why You Should Avoid It - Benzinga
Regeneron Licenses Weight Loss Drug and Shares Data on Muscle Preservation Medicines as Bluebird Bio Goes Private - geneonline.com
Regeneron CIO on balancing biotech innovation with regulatory demands - cio.com
Regeneron makes obesity push; Atai, Alto ink brain drug deals - BioPharma Dive
Regeneron Secures $407M Antitrust Win Over Amgen - USA Herald
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn - PMLiVE
Wolfe Research Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $925 - marketscreener.com
RBC Capital maintains neutral rating on Regeneron stock - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 1-Year LowShould You Sell? - MarketBeat
Is It Time To Buy Regeneron Pharmaceuticals Stock? - Nasdaq
COPD Drug Developed by Regeneron, Sanofi Fails Key Test - MSN
Regeneron Gets $407M After Antitrust Win Over Amgen - Law360
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B - BioWorld MedTech
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):